Three Factors Shape Vaccine Response in IMID
Dr. Henrique Dalmolin & Dr. Licia Mota & Dr. Viviane Souza De Souza | ACR 2026
Transcription
Hey everyone, I'm in Hik. I'm here in Orlando at our coverage for RheumNow at ACR 2026. I'm here with Elicia Motor. I'm here with Vivian Sa, and Vivian will talk more about her study. So, let's talk about a registry from the Brazilian Society of Rheumatology. That's a very important study. And let's talk about what shaped the response to vaccination in patients with rheumatic diseases.
Yeah, this is an important study. This is a subanalysis of this registry, and we are evaluating the humoral response and the inflammatory status of our patients in relation with the SARS-CoV-2 vaccine response.
And how many patients and what were the diagnoses in this subanalysis? We included more than 500 participants. We had 214 patients, mainly lupus patients, about 50% of our sample, and we included 360 healthy controls. And it's important to highlight that all the sample was naive for the infection and were not vaccinated before being included in the study.
Vivian, what were the main results of this study? Well, the first main result is that our patients have a lower response when we compare to healthy controls. We evaluated three vaccine platforms: the Sinovac CoronaVac vaccine, the adenovirus vaccine from AstraZeneca, and the mRNA vaccine, the Pfizer vaccine. And in our patients, the CoronaVac was the one that had the worst response, while the Pfizer vaccine was least influenced — it had a better response than the other platforms.
And before going to the key message, we have another subanalysis where we had a comparison between high and low degree of immune suppression. Across all the vaccine platforms, less so with the Pfizer platform, we had a worse response in patients who had a higher degree of immune suppression. A third result of our study is that we evaluated soluble mediators — 27 soluble mediators — to analyze the inflammatory status. What we saw is that the inflammatory profile of the patients was different at baseline from the healthy controls, and this influenced the vaccine response. Those who were good responders had a profile with a higher predominance of the innate immune system mediators, while those who had a worse response had more of an inflammatory profile.
So let's go to the key message. In our patients, the vaccine responses are influenced not by only one factor, but by the disease itself, the degree of immune suppression that these patients are exposed to, the vaccine platform — we had a different response, Pfizer seems better — and also the inflammatory basal profile. So thank you very much and stay tuned for more.
Yeah, this is an important study. This is a subanalysis of this registry, and we are evaluating the humoral response and the inflammatory status of our patients in relation with the SARS-CoV-2 vaccine response.
And how many patients and what were the diagnoses in this subanalysis? We included more than 500 participants. We had 214 patients, mainly lupus patients, about 50% of our sample, and we included 360 healthy controls. And it's important to highlight that all the sample was naive for the infection and were not vaccinated before being included in the study.
Vivian, what were the main results of this study? Well, the first main result is that our patients have a lower response when we compare to healthy controls. We evaluated three vaccine platforms: the Sinovac CoronaVac vaccine, the adenovirus vaccine from AstraZeneca, and the mRNA vaccine, the Pfizer vaccine. And in our patients, the CoronaVac was the one that had the worst response, while the Pfizer vaccine was least influenced — it had a better response than the other platforms.
And before going to the key message, we have another subanalysis where we had a comparison between high and low degree of immune suppression. Across all the vaccine platforms, less so with the Pfizer platform, we had a worse response in patients who had a higher degree of immune suppression. A third result of our study is that we evaluated soluble mediators — 27 soluble mediators — to analyze the inflammatory status. What we saw is that the inflammatory profile of the patients was different at baseline from the healthy controls, and this influenced the vaccine response. Those who were good responders had a profile with a higher predominance of the innate immune system mediators, while those who had a worse response had more of an inflammatory profile.
So let's go to the key message. In our patients, the vaccine responses are influenced not by only one factor, but by the disease itself, the degree of immune suppression that these patients are exposed to, the vaccine platform — we had a different response, Pfizer seems better — and also the inflammatory basal profile. So thank you very much and stay tuned for more.
Recommended videos
-
Education/ACR/EULAR
Vaccination strategies for the rheumatologist
-
Education/ACR/EULAR
Don’t Hold the JAK (10.9.2026)
-
Education/ACR/EULAR
A Day of Infamy (9.11.2026)

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.